A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease

What Was Tested

This randomized controlled trial paper looks at Somatostatin and Lanreotide.

The researchers tested whether the analogue lanreotide slows glomerular filtration rate (GFR) decline over three years in adults with ADPKD stages 2/3.

Registered at ClinicalTrials.gov with study number NCT02127437.

Who Took Part

The study group was 144 participants.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Due to slow enrollment, recruitment stopped after 144 of 180 planned participants.

All randomized participants were included in the analysis (intention-to-treat).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Somatostatin.

Some participants received a placebo instead of Somatostatin, giving a reference point.

The primary endpoint was mGFR slope (iohexol clearance) assessed at baseline, weeks 72 and 144 and analyzed with a linear mixed-effects model (LMM).

Secondary endpoints included annual estimated GFR decline (creatinine-based, assessed at 11 scheduled visits), kidney events, quality of life, and safety.

What Was Measured

The researchers tested whether the analogue lanreotide slows glomerular filtration rate (GFR) decline over three years in adults with ADPKD stages 2/3.

Topics PubMed links to this paper include Polycystic Kidney, Autosomal Dominant, Peptides, Cyclic, Glomerular Filtration Rate, Somatostatin, Disease Progression, Kidney and Quality of Life.

Author keywords: ADPKD, clinical study, estimated glomerular filtration rate and genetic kidney disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Lanreotide in 144 participants.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Kidney international), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.